Clinical Correlates of Cannabis Use Among Individuals With Attention Deficit Hyperactivity Disorder

被引:11
作者
Brandt, Ariel [1 ]
Rehm, Jurgen [2 ,3 ,4 ]
Lev-Ran, Shaul [1 ,2 ,5 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[2] Inst Mental Hlth Policy Res, Ctr Addict & Mental Hlth, Tel Aviv, Israel
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[4] Tech Univ Dresden, Klin Psychol Psychotherapie, Dresden, Germany
[5] Lev Hasharon Med Ctr, Pardesiya, Israel
关键词
ADHD; cannabis; epidemiology; psychiatric disorders; DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE-USE; YOUNG-ADULTS; ADHD; PREVALENCE; COMORBIDITY; AGREEMENT; SYMPTOMS; SUBTYPES; ALCOHOL;
D O I
10.1097/NMD.0000000000000877
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In this study, we explored patterns and clinical correlates of cannabis use among individuals with attention-deficit/hyperactivity disorder (ADHD). Data were obtained from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (2004-2005). Psychiatric disorders were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule. We used multivariate logistic regression models adjusting for sociodemographics, psychiatric disorders, and substance use disorders. Prevalence of cannabis use among individuals with and without ADHD was 14.3% and 4.3%, respectively. Diagnosis of any psychiatric disorder was significantly higher among those with ADHD and concurrent cannabis use compared with nonusers (adjusted odds ratio [AOR], 2.8; 95% confidence interval [CI], 1.08-6.41), as were odds of a lifetime personality disorder (AOR, 4.04; 95% CI, 1.84-8.84). Individuals with the hyperactive subtype initiated cannabis at a significantly earlier age compared with those with the inattentive subtype (13.8 +/- 0.56 vs. 16.3 +/- 0.5 years, respectively; p = 0.0017). Longitudinal prospective studies are required to further clarify the effects and patterns of cannabis use in this clinical population.
引用
收藏
页码:726 / 732
页数:7
相关论文
共 33 条
[1]  
[Anonymous], WORLD DRUG REP 2016
[2]  
[Anonymous], 2003, RES 2002 NAT SURV DR
[3]  
[Anonymous], 2005, SOURCE ACCURACY STAT, DOI DOI 10.1037/E571832006-001
[4]  
[Anonymous], J ATTEN DISORD
[5]   The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) [J].
Bernardi, S. ;
Faraone, S. V. ;
Cortese, S. ;
Kerridge, B. T. ;
Pallanti, S. ;
Wang, S. ;
Blanco, C. .
PSYCHOLOGICAL MEDICINE, 2012, 42 (04) :875-887
[6]   Attention-deficit/hyperactivity disorder: A selective overview [J].
Biederman, J .
BIOLOGICAL PSYCHIATRY, 2005, 57 (11) :1215-1220
[7]   Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement [J].
Carey, Caitlin E. ;
Agrawal, Arpana ;
Bucholz, Kathleen K. ;
Hartz, Sarah M. ;
Lynskey, Michael T. ;
Nelson, Elliot C. ;
Bierut, Laura J. ;
Bogdan, Ryan .
FRONTIERS IN GENETICS, 2016, 7
[8]  
Carter MJ, 2014, THER RECREAT J, V48, P275
[9]  
Cicchetti D. V., 1994, Psychol Assessment, V6, P284, DOI [DOI 10.1037/1040-3590.6.4.284, 10.1037/1040-3590.6.4.284]
[10]   A COEFFICIENT OF AGREEMENT FOR NOMINAL SCALES [J].
COHEN, J .
EDUCATIONAL AND PSYCHOLOGICAL MEASUREMENT, 1960, 20 (01) :37-46